Patents by Inventor David H. Gutmann

David H. Gutmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Neurofibromin/dopamine signaling as a biomarker for cognitive and behavioral problems in children with neurofibromatosis type 1 (NF1 )
    Patent number: 11085933
    Abstract: The present disclosure is generally related to neurofibromatosis type 1. More particularly, disclosed herein are methods for detecting behavioral disorders, methods for detecting cognitive impairment, and methods for detecting brain neurofibromin-dependent dopaminergic signaling associated with neurofibromatosis type 1.
    Type: Grant
    Filed: October 4, 2019
    Date of Patent: August 10, 2021
    Assignee: Washington University in St. Louis
    Inventors: David H. Gutmann, Corina Anastasaki
  • NEUROFIBROMIN/DOPAMINE SIGNALING AS A BIOMARKER FOR COGNITIVE AND BEHAVIORAL PROBLEMS IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1 (NF1)
    Publication number: 20200041527
    Abstract: The present disclosure is generally related to neurofibromatosis type 1. More particularly, disclosed herein are methods for detecting behavioral disorders, methods for detecting cognitive impairment, and methods for detecting brain neurofibromin-dependent dopaminergic signaling associated with neurofibromatosis type 1.
    Type: Application
    Filed: October 4, 2019
    Publication date: February 6, 2020
    Inventors: David H. Gutmann, Corina Anastasaki
  • NEUROFIBROMIN/DOPAMINE SIGNALING AS A BIOMARKER FOR COGNITIVE AND BEHAVIORAL PROBLEMS IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1 (NF1)
    Publication number: 20160370383
    Abstract: The present disclosure is generally related to neurofibromatosis type 1. More particularly, disclosed herein are methods for detecting behavioral disorders, methods for detecting cognitive impairment, and methods for detecting brain neurofibromin-dependent dopaminergic signaling associated with neurofibromatosis type 1.
    Type: Application
    Filed: June 20, 2016
    Publication date: December 22, 2016
    Inventors: David H. Gutmann, Corina Anastasaki
  • Neurofibromatosis gene
    Patent number: 6238861
    Abstract: The invention relates to the gene involved in the von Recklinghausen neurofibromatosis (NF1) disease process and to the identification, isolation and cloning of a nucleic acid sequence corresponding to the gene. The invention further relates to the NF1 gene product and sequence and antibodies raised thereto. The invention also relates to methods of screening for NF1 and NF1 diagnosis, as well as conventional treatment and gene therapy utilizing recombinant technologies.
    Type: Grant
    Filed: August 2, 1993
    Date of Patent: May 29, 2001
    Assignee: The Regents of the University of Michigan
    Inventors: Francis S. Collins, Margaret R. Wallace, Douglas A. Marchuk, Lone B. Andersen, David H. Gutmann
  • Neurofibromatosis gene
    Patent number: 5859195
    Abstract: The entire coding region of the gene involved in von Recklinghausen neurofibromatosis (NF1) and a ubiquitously expressed large transcript (NF1LT) of the gene have been identified, cloned and sequenced. With the identification of the NF1 gene and its gene product, nucleic acid probes and antibodies raised to the gene product can be used in a variety of hybridization and immunological assays to screen for NF1 and detect it in its early stages. Conventional and gene therapies can also be developed to treat those afflicted with the disease.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: January 12, 1999
    Assignee: The Regents of the University of Michigan
    Inventors: Francis S. Collins, Margaret R. Wallace, Douglas A. Marchuk, Lone B. Andersen, David H. Gutmann